A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
IGC is a Maryland corporation established in 2005 with a fiscal year ending on March 31, spanning a 52- or 53-week period. Please refer to Note 1, “Nature of Operations” and Item 8 of this Annual Report on Form 10-K, for further information on business segments. Our mission is to improve the lives of individuals affected by Alzheimer’s disease by addressing both its symptoms and the disease. Our near-term focus is on advancing IGC-AD1, our lead drug candidate currently in Phase 2 clinical trials targeting agitation in Alzheimer’s patients. We are also investing in our early-stage pipeline of investigational therapies and exploring Artificial Intelligence (AI) powered models designed to identify early markers of Alzheimer’s. We believe that combining scientific innovation with operational execution, including leveraging our internal contract research organization, positions us to efficiently advance our pipeline toward commercialization, although there can be no assurance thereof.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.9M | - | - | - | - | - |
| Net Income | -16M | -7.1M | -13M | -12M | -15M | -8.8M |
| EPS | $-0.25 | $-0.09 | $-0.22 | $-0.22 | $-0.30 | $-0.21 |
| Free Cash Flow | -7.4M | -4.9M | -5.3M | -7.4M | -7.7M | -12M |
| ROIC | -182.9% | -103.8% | -150.3% | -76.4% | -62.5% | -26.6% |
| Gross Margin | 51.3% | - | - | - | - | - |
| Debt/Equity | 0.02 | 0.02 | 0.03 | 0.02 | 0.02 | 0.03 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -13M | -7.4M | -9.8M | -12M | -15M | -8.7M |
| Operating Margin | -677.4% | - | - | - | - | - |
| ROE | -253.2% | -104.3% | -177.6% | -77.2% | -62.8% | -26.9% |
| Shares Outstanding | 84M | 79M | 59M | 52M | 50M | 42M |
IGC Pharma, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
IGC Pharma, Inc. (IGC) has a 5-year average return on invested capital (ROIC) of -83.9%. This is below average and may indicate limited pricing power.
IGC Pharma, Inc. (IGC) has a market capitalization of $26M. It is classified as a small-cap stock.
IGC Pharma, Inc. (IGC) does not currently pay a regular dividend.
IGC Pharma, Inc. (IGC) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
IGC Pharma, Inc. (IGC) generated $-5 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
IGC Pharma, Inc. (IGC) has a debt-to-equity ratio of 0.02. This indicates a conservatively financed balance sheet.
IGC Pharma, Inc. (IGC) reported earnings per share (EPS) of $-0.09 in its most recent fiscal year.
IGC Pharma, Inc. (IGC) has a return on equity (ROE) of -104.3%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 15 years of financial data for IGC Pharma, Inc. (IGC), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
IGC Pharma, Inc. (IGC) has a book value per share of $0.08, based on its most recent annual SEC filing.